[Form 4] Core Laboratories Inc. Insider Trading Activity

Rhea-AI Filing Summary

Core Laboratories Inc. (CLB) – Form 4 insider update. On 08/01/2025, Chief Accounting Officer & Treasurer Teo Sow Hang reported multiple transactions involving the company’s common stock.

• Restricted-share vesting: 200 and 240 restricted shares converted to common stock (Code M) at a stated price of $0, adding 440 shares.
• Dispositions: 90 and 108 shares were disposed of (Code F) at $10.53 per share, totaling 198 shares sold.
• Net share change: +242 shares for the day, bringing the officer’s direct holdings to 7,748.334 common shares.
• Derivative position: Following the transactions, 8,004 restricted shares remain outstanding.

The filing reflects routine vesting and tax-related sales with a modest increase in ownership. No information on 10b5-1 plans, market impact, or company fundamentals is provided.

Insights

Financial Analyst

TL;DR: Routine vesting; immaterial to CLB valuation.

The CAO’s Form 4 shows 440 restricted shares vesting and 198 shares sold for $10.53, netting a 242-share increase. The total value traded (≈$2.1 k) is negligible relative to CLB’s market cap, so the event is non-impactful for investors. Such filings are common around vesting anniversaries and do not signal a strategic shift or altered insider sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teo Sow Hang

(Last) (First) (Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON TX 77040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CAO & Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		F		90	D	$10.53	7,750.334	D
Common Stock	08/01/2025		M		200	A	$0	7,840.334	D
Common Stock	08/01/2025		F		108	D	$10.53	7,640.334	D
Common Stock	08/01/2025		M		240	A	$0	7,748.334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	(1)	08/01/2025		M			200	(1)	(1)	Common Stock	200	$0	7,804(2)	D
Restricted Shares	(1)	08/01/2025		M			240	(1)	(1)	Common Stock	240	$0	8,004(2)	D

Explanation of Responses:

1. The Restricted Shares vest annually over six years on the anniversary of the grant date in the amount specified in the award agreement, provided the reporting person remains in continuous service on each such vesting date.

2. Multiple restricted share grants are included in this total.

	/s/ Mark Tattoli, Attorney-in-Fact	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CLB shares did CAO Teo Sow Hang acquire on 08/01/2025?

440 restricted shares converted to common stock, recorded as acquisitions (Code M).

What price were Core Laboratories shares sold for in the filing?

Dispositions were reported at $10.53 per share.

What is the officer’s total direct holding after the transactions?

The Form 4 lists 7,748.334 CLB common shares held directly.

Does the Form 4 indicate use of a 10b5-1 trading plan?

No. The filing does not check the 10b5-1(c) box, so no plan is disclosed.

Are these transactions material to Core Laboratories shareholders?

Given the small dollar value and share count, the filing is considered not material to overall shareholder value.